Publications by authors named "K Porkka"
Article Synopsis
- The study addresses the challenge of treating advanced cancers, where cellular diversity requires therapies targeting multiple cancer cell populations.* -
- A machine learning tool called scTherapy uses single-cell transcriptomic data to identify personalized multi-targeting treatment options for patients with various cancers, like acute myeloid leukemia and ovarian carcinoma.* -
- Results show that 96% of the proposed treatments are effective and selective for cancer cells, with 83% having low toxicity to healthy cells, suggesting a promising avenue for safer and more effective cancer therapies.*
The B-cell lymphoma 2 inhibitor venetoclax has shown promise for treating acute myeloid leukemia (AML). However, identifying patients likely to respond remains a challenge, especially for those with relapsed/refractory (R/R) disease. We evaluated the utility of ex vivo venetoclax sensitivity testing to predict treatment responses to venetoclax-azacitidine in a prospective, multicenter, phase 2 trial.
View Article and Find Full Text PDFBCR::ABL1-independent pathways contribute to primary resistance to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) and play a role in leukemic stem cell persistence. Here, we perform ex vivo drug screening of CML CD34 leukemic stem/progenitor cells using 100 single drugs and TKI-drug combinations and identify sensitivities to Wee1, MDM2, and BCL2 inhibitors. These agents effectively inhibit primitive CD34CD38 CML cells and demonstrate potent synergies when combined with TKIs.
View Article and Find Full Text PDFArticle Synopsis
- In many cancers, including acute myeloid leukemia (AML), the challenge of relapse often involves multidrug resistance (MDR) linked to changes in cancer cell genetics.
- Researchers employed acute myeloid leukemia patient-derived xenografts (PDX) to explore drug sensitivity and resistance mechanisms, revealing that resistance often correlates with diminished mitochondrial apoptotic priming and affects responses to various drug types.
- Their findings suggest that by using dynamic BH3 profiling (DBP), it's possible to identify effective drugs for patients experiencing drug-resistant relapses, highlighting the potential for this method in developing personalized treatment strategies.
Venetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523). Here, long-term follow-up is presented to address survival benefit and long-term outcomes with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azacitidine or placebo-azacitidine.
View Article and Find Full Text PDF